India's Shilpa Medicare can make 100-200 million doses of Covid-19 shot
Indian drug
maker Shilpa Medicare Ltd has the
production capacity to make 100-200 million doses of a recombinant vaccine for COVID-19, a company executive
told Reuters on Wednesday.
The
company's shares jumped as much as 9.2% on India's National Stock Exchange
following the news. Read More
Comments
Post a Comment